Sho-saiko-to, a traditional Kampo medicine, enhances the anti-HIV-1 activity of lamivudine (3TC) in vitro

Microbiology and Immunology

Volumn 41, Issue 10, 1997, Pages 835-839

  Piras, Giovanna ^a,b   Makino, Masahiko ^a   Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Istituto di Farmacologia   (Italy)

Author keywords

3TC; Combination chemotherapy; HIV 1; Sho saiko to

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; LAMIVUDINE; XIAO CHAI HU TANG; ZIDOVUDINE;

ANTIBODY RESPONSE; ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; TRADITIONAL MEDICINE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030723343     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.1997.tb01937.x     Document Type: Article

References (24)

1. Baba, M., Shigeta, S., Yuasa, S., Takashima, H., Sekiya, K., Ubasawa, M., Tanaka, H., Miyasaka, T., Walker, R.T., and De Clercq, E. 1994. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38: 688-692.
2. Bartlett, J.A., Benoit, S.L., Johnson, V.A., Quinn, J.B., Sepulveda, G.E., Ehmann, C., Tsoukas, C., Fallon, M.A., Self, P.L., and Rubin, M., for the North American HIV Working Party. 1996. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125: 161-172.
3. Buimovici-Klein, E., Mohan, V., Lange, M., Fenamore, E., Inada, Y., and Cooper, L.Z. 1990. Inhibition of HIV replication in lymphocyte cultures of virus-positive subjects in the presence of Sho-saiko-to, an oriental plant extract. Antiviral Res. 14: 279-286.
4. Condra, J.H., Schleif, W.A., Blahy, O.M., Gabryelski, L.J., Graham, D.J., Quintero, J.C., Rhodes, A., Robbins, H.L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K.E., Deutsch, P.J., and Emini, E.A. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571.
5. D'Aquila, R.T., Hughes, M.D., Johnson, V.A., Fischl, M.A., Sommadossi, J.-P., Liou, S.-H., Timpone, J., Myers, M., Basgoz, N., Niu, M., Hirsch, M.S., and the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. 1996. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 124: 1019-1030.
6. De Clercq, E. 1995. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8: 200-239.
7. Delta Coordinating Committee. 1996. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283-291.
8. Frissen, P.H.J., van der Ende, M.E., Napel, C.H.H.T., Weigel, H.M., Schreij, G.S., Kauffmann, R.H., Koopmans, P.P., Hoepelman, A.I.M., de Boer, J.B., Weverling, G.J., Haverkamp, G., Dowd, P., Miedema, F., Schuurman, R., Boucher, C.A.B., and Lange, J.M.A. 1994. Zidovudine and interferon-α combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. J. Infect. Dis. 169: 1351-1355.
9. Gulick, R.M., Mellors, J., Havlir, D., Eron, J., Gonzalez, C., McMahon, D., Richman, D., Valentine, F., Rooney, J., Jonas, L., Meibohm, A., Emini, E., and Chodakewitz, J. 1996. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). XI International Conference on AIDS, Abstract Th.B. 931.
10. Hammer, S.M., Katzenstein, D.A., Hughes, M.D., Gundacker, H., Schooley, R.T., Haubrich, R.H., Keith Henry, W., Lederman, M.M., Phair, J.P., Niu, M., Hirsch, M.S., and Merigan, T.C., for the AIDS Clinical Trial Group Study 175 Study Team. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New Engl. J. Med. 335: 1081-1090.
11. Kitamura, K., Honda, M., Yoshizaki, H., Yamamoto, S., Nakane, H., Fukushima, M., Ono, K., and Tokunaga, T. 1997. Baicalin, a potent inhibitor of HIV-1 production in vitro. Antiviral Res. in press.
12. Krown, S.E., Gold, J.W.M., Niedzwiecki, D., Bundow, D., Flomenberg, N., Gansbacher, B., and Brew, B.J. 1990. Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 112: 812-821.
13. Larder, B.A., Darby, G., and Richman, D.D. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
14. Livington, D.J., Pazhanisamy, S., Porter, D.J., Partaledis, J.A., Tung, R.D., and Painter, G.R. 1995. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J. Infect. Dis. 172: 1238-1245.
15. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc. Natl. Acad. Sci. U.S.A. 92: 2308-2312.
16. Markowitz, M., Cao, Y., Hurley, Y., O'Donovan, R., Heath-Chiozzi, M., Leonard, J., Smiley, L., Keller, A., Johnson, D., Johnson, P., and Ho, D.D. 1996. Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. XI International Conference on AIDS, Abstract Th.B. 933.
17. Miyoshi, I., Taguchi, H., Kubonishi, I., Yoshimoto, S., Ohtsuki, Y., Shiraishi, Y., and Akagi, T. 1982. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr. 28: 219-228.
18. Ono, K., Nakane, H., Fukushima, M., Chermann, J.-C., and Barré-Sinoussi, F. 1989. Inhibition of reverse transcriptase activity by a flavonoid compound, 5,6,7-trihydroxyflavone. Biochem. Biophys. Res. Commun. 160: 982-987.
19. Ono, K., Nakane, H., Fukushima, M., Chermann, J.C., and Barré-Sinoussi, F. 1990. Differential inhibition of the activities of reverse transcriptase and various cellular DNA polymerases by a traditional Kampo drug, Sho-saiko-to. Biomed. Pharmacother. 44: 13-16.
20. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and De Clercq, E. 1988. Rapid and automated tetrazolium-based colorimetric assay for detection of anti-HIV compounds. J. Virol. Methods 20: 309-321.
21. Piras, G., Nakade, K., Yuasa, S., and Baba, M. 1997. Three-drug combination of MKC-442, 3TC and AZT in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS 11: 469-475.
22. St. Clair, M.H., Martin, J.L., Tudor-Williams, G., Bach, M.C., Vavro, C.L., King, D.M., Kellam, P., Kemp, S.D., and Larder, B.A. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253: 1557-1559.
23. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234: 1563-1566.
24. Watanabe, K., Inada, Y., Ikegami, H., Senderowicz, A., Kamiyama, M., Kanemitsu, T., Sulzberger, J.P., Clark, W.S., and Lange, M. 1990. In-vitro immunomodulatory effects of traditional Kampo medicine on peripheral mononuclear cells from patients with HIV infection. Int. J. Oriental Med. 15: 1-9.